275 Armand-Frappier Boulevard
36 articles with BELLUS Health
BELLUS Health Announces Exercise of Over-Allotment Option in Connection With Underwritten Public Offering of Common Shares
Company has raised total gross proceeds of approximately US$79.37 million from the Offering, before deducting the underwriting commissions and any expenses related to the Offering.
The Company has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,478,873 common shares from the Company on the same terms and conditions.
In connection with its previously announced public offering of common shares in Canada and the United States, BELLUS Health Inc., announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Cowen and Guggenheim Securities, as joint book-running managers, Baird, as lead manager, and Bloom Burton Securities, as co-manager
BELLUS Health Announces the Launch of a US$60 Million Public Offering of Common Shares in Canada and the United States and the Filing of an Application to List Its Common Shares on Nasdaq
BELLUS Health Inc., announced the filing of a preliminary prospectus supplement to its short form base shelf prospectus dated July 26, 2019 in connection with a proposed US$60 million public offering of its common shares, and the filing of an application to list its common shares on the Nasdaq Global Market in the United States under the ticker “BLU”.
BELLUS Health Strengthens Leadership Team with Appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
BELLUS Health Inc. announced the appointment of Dr. Catherine Bonuccelli, MD to the role of Chief Medical Officer.
BELLUS Health Inc. announced that it is proceeding with a 3.6:1 consolidation of the Company’s common shares with an effective date of August 19, 2019.
BELLUS Health Inc. reported its financial and operating results for the second quarter ended June 30, 2019.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic Pruritus
BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, announced that the first patient has been enrolled in the RELIEF Phase 2 study of BLU-5937 in chronic cough.
Professor Jacky Smith from the University of Manchester to lead live webcast
BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today presented results from the clinical Phase 1 study of BLU-5937, an orally-administered P2X3 antagonist, being developed for the treatment of refractory chronic cough
BELLUS Health Inc. announced that Roberto Bellini, President and Chief Executive Officer of BELLUS Health, will present a corporate overview of the Company, including an update on its lead program BLU-5937 for the treatment of chronic cough, at three upcoming healthcare investor conferences.
BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019
Two abstracts, including data from the clinical Phase 1 study for BLU-5937, were accepted for presentation at the American Thoracic Society Conference on May 21 and at the American Cough Conference on June 7
8/28/2018In April, Alzheon attempted an initial public offering (IPO) to raise $80 million, but withdrew the offering. It has decided to try again, filing with the U.S. Securities and Exchange Commission (SEC), indicating it planned to raise $40 million in an IPO.
Study Results Expected in the Fourth Quarter of 2018
5/1/2018Biopharmaceutical companies are focusing their drugs for smaller and smaller and more clearly delineated patient populations. No longer is a drug for lung cancer or even non-small cell lung cancer, but a much smaller segment.
The majority of the Offering was subscribed to by healthcare specialized institutional investors and also included the participation by members of the senior management team and board of directors of the Company.
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Completion Of Enrollment In The Phase III Confirmatory Study of Kiacta For The Treatment Of AA Amyloidosis
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Engagement Of Financial Advisor To Explore Sale Of KIACTA™, An Experimental Drug In Phase 3 Development For The Treatment Of AA Amyloidosis
Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) And BELLUS Health Announce Licence Agreement With Mount Sinai For KIACTATM In Sarcoidosis